基本信息
views: 15
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Prof. Parren is dedicated to translate antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He has a passion for investigating and understanding structure-function relationships and translating the knowledge gained into immunotherapy applications and drug development. He is an inventor of the therapeutic antibodies ofatumumab (Arzerra, Kesimpta) daratumumab (DARZALEX), teprotumumab (Tepezza), tisotumab vedotin (Tivdak) en amivantamab (Rybrevant). Ofatumumab was approved in 2009 for the treatment of Chronic Lymphocytic Leukemia and in 2020 in a subcutaneous formulation for Multiple Sclerosis. Ofatumumab received the Dutch Galenus Prize in 2011 for most innovative new medicine. Ofatumumab (Arzerra) has, for the treatment of cancer, since been transitioned to compassionate use and oncology access programs. Daratumumab was first approved in 2015 for the treatment of Multiple Myeloma. Teprotumumab was approved for the treatment of Active Thyroid Eye Disease (Graves’ orbitopathy in 2020. Tisotumab vedotin (an antibody-drug conjugate) and amivantamab (an EGFR-cMet bispecific antibody) were approved in 2021 by FDA for the treatment of recurrent or metastatic cervical cancer and for metastatic NSCLC with EGFR exon 20 insertion, respectively. Paul Parren further invented and developed several clinically translated technologies aimed at improving antibody therapy, including bispecific antibodies and effector function-enhanced antibodies (DuoBody and HexaBody platforms). The first bispecific antibody product based on the DuoBody technology obtained regulatory approval in 2021. His work has thus far directly led to four therapeutic antibodies that received FDA Breakthrough Therapy designation and ten further therapeutic antibodies in various formats currently in clinical development for the treatment of cancer and Parkinson’s disease.
Research Interests
Papers共 500 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER GENE THERAPYno. 1 (2024): 58-68
Frontiers in immunology (2024): 1288597-1288597
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Load More
Author Statistics
#Papers: 505
#Citation: 35299
H-Index: 97
G-Index: 179
Sociability: 8
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn